Amplius Wealth Advisors’s Biogen BIIB Stock Holding History

Amplius Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-118	Closed	-$28K	–	249
2021 Q4	$28K	Buy	+118	New	+$30.3K	﹤0.01%	413

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Amplius Wealth Advisors's BIIB Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of Biogen (BIIB) in Q1 2022, closing a stake of 118 shares — an estimated $28K sold.

Amplius Wealth Advisors first reported a position in BIIB in Q4 2021 and held it in 1 quarter. The position peaked at $28K in Q4 2021. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

Amplius Wealth Advisors reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
Amplius Wealth Advisors sold 118 Biogen shares in Q1 2022, an estimated $28K.
Amplius Wealth Advisors first reported a position in Biogen in Q4 2021 and held it in 1 quarter.
Amplius Wealth Advisors's Biogen position peaked at $28K in Q4 2021.
951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.